Objective-To compare high energy fast neutron treatment with conventional megavoltage x ray treatment in the management of locally advanced pelvic carcinomas (of the cervix, bladder, prostate, and rectum).
Introduction
Compared with conventional megavoltage radiotherapy (with photons) high linear energy transfer radiation such as neutron beams has potential biological advantages that may lead to improved overall results when used to treat locally advanced tumours.' These advantages were not shown, however, in randomised studies on the treatment of rectal cancer and cancer of the bladder with low energy neutron beams2-6 and carcinoma of the cervix with mixed photon and neutron treatment schedules. Of the studies of mixed photon and neutron treatment only the one in patients with cancer of the prostate showed an advantage when neutrons were used as part of the radiation treatment,89 but the validity of this observation has been questioned. '0 Mixed photon and neutron treatment schedules were evolved to overcome the logistic problems posed by limited access to non-hospital based cyclotrons and were not based on any radiobiological rationale.'" Low energy neutrons are associated with excess morbidity when used alone to treat pelvic tumours, which may obscure any benefit to be derived from neutrons if they could be used to irradiate pelvic tumours with dose distributions similar to those obtained with megavoltage x rays.'"2
More recently, hospital based cyclotrons capable of producing high energy neutrons have been developed, and there is registry based evidence that these are associated with greatly reduced morbidity when used to treat patients with pelvic tumours. 4 In view of this, further phase three randomised studies of treatment with high energy neutrons versus treatment with photons were initiated in patients with locally advanced pelvic tumours (of the cervix, bladder, prostate, and rectum) to define the role of neutron treatment at these sites and determine whether or not the potential biological advantages are real in terms of clinical outcomes.
The research programme at Clatterbridge Hospital had the following positive features: high energy neutron treatment was compared with modern megavoltage photon treatment; patient follow up on site and by research clinicians; randomisation from the outset, with a ratio of patients allocated to neutron treatment compared those allocated to photon treatment of 3 to 1 from 6 February 1986 until 11 January 1988, when the ratio was changed to 1 to 1 randomisation by permuted blocks of variable length and stratified by site of tumour; dual planning of eligible patients to avoid "non-evaluable" bias-patients were randomised only if the plans for both neutron and photon treatment were acceptable; a careful informed consent procedure.
Poor patient accrual was one argument for combining patients with cancer at different sites (cervix, bladder, rectum, and prostate) within a single randomised trial; site specific trials would have been entirely lacking in statistical power. A second reason was that although the specific tissues affected by morbidity due to radiation might differ among patients with cancer at different sites, the pooled data would give a clearer indication of whether morbidity was becoming the serious problem it had been shown to be when low energy neutrons were used. Treatment in all patients was planned with a treatment simulator that incorporated information from diagnostic and planning computed tomograms. In all patients an initial large volume of the pelvis was treated to cover the primary tumour and pelvic lymph nodes. This was followed by a second phase, entailing treatment of a small volume of the pelvis, replanned on the basis of computed tomograms, to treat the primary tumour site with a 2 cm margin around the area of known macroscopic disease. In patients with cervical cancer intracavity treatment was given whenever possible after the first phase of pelvic radiotherapy and was followed, where appropriate, with a boost treatment to a small volume of the parametrium. Table I gives the dose schedules for each site.
For both neutron and photon treatment comparable dose distributions were achieved as confirmed by dual planning in the early phase of the study (see below). Three and four field techniques were used and plans accepted only when the variation of dose within the target volume did not deviate by more than 7 5% of the target absorbed dose (as specified in section 33 6 February 1986 to 10 January 1988) 56 patients were randomised in the ratio of 3 to 1-42 to neutron treatment and 14 to photon treatment -but without stratification by site of tumour. Block length (eight) was not disclosed to clinicians, and randomisation was performed at the hospital by using sealed envelopes prepared by one of us (SMG).
Dual planning (for neutron and photon treatment) for eligible patients was practised for the first 50 patients; all were in fact randomised because they had adequate radiotherapy plans for both modalities. Dual planning was then suspended. Analysis by intention to treat was adhered to strictly with no patient excluded from the analysis retrospectively on grounds of inadequacy of radiotherapy plan, thus avoiding nonevaluable bias.
From 11 January 1988, 1 to 1 randomisation (again by using sealed envelopes) by permuted blocks of length four or six (determined by simple randomisation) and stratified by site of tumour was adopted for patients with tumours of the cervix, bladder, rectum, or prostate. PATIENT 
Results
By 26 January 1990, 151 patients had been randomised. Table II shows how they were distributed by site of tumour, phase of randomisation, and treatment. Accrual was 70% higher in the second phase compared with the first, with recruitment doubled for patients with cancer of the cervix or bladder. Figure 1 shows the estimated survivor function by treatment for cancers at all sites combined. BMJ VOLUME 302 Table IV Table V shows the risk score summation for site of tumour, T and N stage, and Karnofsky index. Table VI shows the distribution of this risk score for both treatment groups. On average the patients treated with neutrons had a worse prognosis than those treated with photons in the first phase, when randomisation was not stratified by site of tumour, and patients with cancers of the rectum and bladder were overrepresented in the neutron group. This explains why the adjusted relative risk is slightly nearer to unity than the unadjusted relative risk. Another issue is clinical significance versus statistical significance. In this trial the difference in mortality was large, but the primary difference between the results of the first informal analysis and those presented formally for the data monitoring committee was that the statistical significance of the relative risk for mortality changed from p=0 07 to p=0 025, which gave stronger evidence against the null hypothesis of no treatment difference. The important yardstick, however, is not equality of effect but the difference that would be required to change clinical practice. This was estimated in March 1988 to be a 30% greater failure rate for photon treatment by the respondents to the inquiry made by one of us (SMG). This difference was well outside the 95% confidence interval, even at the first informal analysis, and it could be argued that the trials should have been suspended on those grounds alone.
There was an intrinsic asymmetry between the two treatments, with one being an established treatment readily available to patients not in the trial and the other being an experimental treatment available at only one site in the United Kingdom. Had the difference been in the reverse direction, in favour of neutron treatment, the trial would be continuing in order to get a better estimate of the superiority of the new treatment. Ethically this would have been justified by considerations of limited resources-that is, that neutron treatment could not currently be offered to all patients. This is in contrast with drugs trials, where it is often feasible quickly to make a new treatment widely available. However, in this trial, with the new treatment showing an adverse effect, to have continued with the trial to gain a better estimate of the difference between neutron and photon treatments would have BMJ VOLUME 302 4 MAY 1991 entailed continuing to randomise some patients to a treatment with an almost certainly worse prognosis than the treatment they would have received if they did not enter the trial. Randomisation was suspended by one of us (RDE) in February 1990 because it was thought to be unethical to continue to randomise patients. Monitoring of patients continues, and to that extent more information on neutron treatment versus photon treatment will become available, especially as regards morbidity in the survivors.
A lesson learnt from this trial is that all trials of this kind, with mortality as an outcome and potentially causing severe toxicity, should have a data monitoring committee in place from the start of the trial. Its role is to decide how and when to monitor results and to share responsibility for decisions to stop or continue trials. This avoids the difficult situation where individual clinicians are forced to make these decisions with little external support or guidance.
In the low energy neutron studies in patients with cancer of the bladder the increased mortality associated with neutrons was related to increased morbidity compared with that caused by photons rather than differences in local tumour control or metastatic relapse.2 This contrasts with the present study, in which the morbidity data showed no significant difference between neutron treatment and photon treatment. This observation, however, needs to be interpreted with caution as follow up times were short and the poor survival of patients treated with neutrons depleted the number available for the full assessment of more serious late complications. Despite this reservation the assumption that high energy neutrons, with improved physical dosimetry, would be associated with less normal tissue morbidity may be correct. This does not, however, lead to any benefit from high energy neutron treatment in terms of survival or freedom from metastatic disease.
We emphasise that these conclusions are not applic- 
Patients and methods
We studied patients referred from local general practitioners. In many cases the referral was a recognition of the need for clarification before labelling the patient as allergic; sometimes "penicillin allergy" had been casually mentioned in the course of history taking. For a few patients treatment with penicillin was indicated and it was necessary to determine whether they were allergic or not. Patients with a classic history of skin rash after receiving ampicillin during an Epstein-Barr type of virus infection were not included.
During 1983-90 there were 175 such referrals to the allergy clinic of this hospital and 144 patients attended as requested; table I shows their sex and age range. In BMJ VOLUME 302
